An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Inclusion Criteria:

• A diagnosis of ulcerative colitis (UC), with signs and symptoms consistent with UCfor at least 3 months prior to the first study intervention administration

• Moderate to severely active UC disease activity, defined as a modified Mayo score of 4 through 9, inclusive, with the following minimum subscores: i) An SF subscore ≥ 1, AND ii) An RB subscore ≥ 1, AND iii) An ES ≥ 2 (endoscopyperformed within 60 days of the first study intervention administration).

• Report of a previous colonoscopy that documents extent of disease

Exclusion Criteria:

• Current or recent (within 3 months of screening) evidence of fulminant colitis,toxic megacolon, or bowel perforation

• Extensive colonic resection or current stoma

• Colonic dysplasia that has not been removed

Other protocol-defined inclusion/exclusion criteria apply